id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0513-0017,FDA,FDA-2011-N-0513,"FDA/OC/CDER to G. Matthew Warren, Senior Regulatory Counsel, March 30, 2012- Letter",Other,Letter(s),2012-04-02T04:00:00Z,2012,4,2012-04-02T04:00:00Z,,2012-04-02T13:55:23Z,,0,0,0900006480fe5c91
FDA-2011-N-0513-0016,FDA,FDA-2011-N-0513,"FDA/OC/CDER to G. Matthew Warren, Senior Regulatory Counsel, February 17, 2012- Letter",Other,Letter(s),2012-02-21T05:00:00Z,2012,2,2012-02-21T05:00:00Z,,2012-02-21T16:57:50Z,,0,0,0900006480fbaca1
FDA-2011-N-0513-0015,FDA,FDA-2011-N-0513,"ISTA Pharmaceuticals, Inc. (Covington & Burling, LLP) February 2, 2012 - Letter",Other,Letter(s),2012-02-16T05:00:00Z,2012,2,2012-02-16T05:00:00Z,,2012-02-21T16:40:27Z,,0,0,0900006480fb87df
FDA-2011-N-0513-0012,FDA,FDA-2011-N-0513,Covington & Burling - Letter,Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:22:50Z,,0,0,0900006480f89793
FDA-2011-N-0513-0014,FDA,FDA-2011-N-0513,"FDA/OC/CDER to G. Matthew Warren, Senior Regulatory Counsel - Letter",Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:51:20Z,,0,0,0900006480fa2836
FDA-2011-N-0513-0013,FDA,FDA-2011-N-0513,"FDA/OC Letter to Parties from the Office of the Commissioner, dated December 30, 2011 - Letter",Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:27:54Z,,0,0,0900006480fa27a9
FDA-2011-N-0513-0011,FDA,FDA-2011-N-0513,"ISTA Pharmaceuticals, Inc. (Covington & Burling, LLP) - Letter",Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:20:10Z,,0,0,0900006480f8a7cf
FDA-2011-N-0513-0010,FDA,FDA-2011-N-0513,"FDA/OC and ISTA Pharmaceuticals to G. Mathew Warren, FDA  Senior Regulatory Counsel, December 16, 2011 - Letter",Other,Letter(s),2011-12-22T05:00:00Z,2011,12,2011-12-22T05:00:00Z,,2011-12-22T17:27:13Z,,0,0,0900006480f88124
FDA-2011-N-0513-0009,FDA,FDA-2011-N-0513,"FDA/CDER to Margaret A. Hamburg, M.D., FDA Commissioner - Letter",Other,Letter(s),2011-12-06T05:00:00Z,2011,12,2011-12-06T05:00:00Z,,2011-12-06T14:48:06Z,,0,0,0900006480f7c1ae
FDA-2011-N-0513-0008,FDA,FDA-2011-N-0513,"FDA/CDER to Margaret A. Hamburg, M.D. , FDA Commissioner - Response to November 7, 2011 Letter",Other,Response(s),2011-11-30T05:00:00Z,2011,11,2011-12-01T05:00:00Z,,2011-12-01T15:07:48Z,,0,0,0900006480f77f33
FDA-2011-N-0513-0007,FDA,FDA-2011-N-0513,"FDA/OC to ISTA Pharmaceuticals, Inc. (Covington & Burling LLP) and Staff Attorney - Memo with attached letter",Other,Memo,2011-11-16T05:00:00Z,2011,11,2011-11-16T05:00:00Z,,2011-11-16T21:42:37Z,,0,0,0900006480f6df5b
FDA-2011-N-0513-0004,FDA,FDA-2011-N-0513,"FDA/OC to Staff Attorneys re: Separation of Functions, September 1, 2011 - Memorandum",Other,Memorandum,2011-10-13T04:00:00Z,2011,10,2011-10-13T04:00:00Z,,2011-12-22T15:56:09Z,,0,0,0900006480f51637
FDA-2011-N-0513-0002,FDA,FDA-2011-N-0513,"Proposals to Refuse to Approve Supplemental New Drug Applications: Bromday (Bromfenac Ophthalmic Solution), 0.09; Opportunity for Hearing",Notice,Notice of Opportunity of Hearing,2011-08-03T04:00:00Z,2011,8,2011-08-03T04:00:00Z,2011-10-04T03:59:59Z,2012-03-24T19:36:44Z,2011-19566,0,0,0900006480ed4a69
FDA-2011-N-0513-0001,FDA,FDA-2011-N-0513,"FDA/CDER to ISTA Pharmaceuticals, Inc. (Covington & Burling LLP) - Letter",Other,Letter(s),2011-07-13T04:00:00Z,2011,7,2011-07-13T04:00:00Z,2011-11-11T04:59:59Z,2011-07-13T18:50:02Z,,0,0,0900006480ec14a6